NON-REDUCING END OF UNSATURATED MANNURONIC ACID OLIGOSACCHARIDE, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

• Main Author: KIM, Du Woon
• Format: Patent
• Language: English; French; Korean
• Published: 06.10.2016
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The present invention relates to a non-reducing end of unsaturated mannuronic acid oligosaccharide, the oligosaccharide being degraded by an alginate lyase with a poly-mannuronate substrate and having a molecular weight of at least 100-3000 Da. The present invention provides: the non-reducing end of unsaturated mannuronic acid oligosaccharide; and a pharmaceutical composition for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and a probiotic for promoting intestinal beneficial bacteria, both of which contain the same as an active ingredient. According to the present invention, anti-obesity, anti-diabetic, and estrogenic activity effects and an effect of regulating intestinal microbiota of the present invention are remarkably excellent compared to those of a mannuronic acid oligosaccharide of a non-reducing end of saturated mannuronic acid oligosaccharides. La présente invention concerne une extrémité non réductrice d'oligosaccharides d'acide mannuronique insaturé, l'oligosaccharide étant dégradé par une alginate lyase avec un substrat poly-mannuronate et ayant un poids moléculaire d'au moins 100 à 3 000 Da. La présente invention concerne : l'extrémité non réductrice d'oligosaccharide d'acide mannuronique insaturé et une composition pharmaceutique destinée à atténuer, prévenir ou traiter l'obésité, le diabète et le syndrome climactérique, et un probiotique permettant d'activer des bactéries intestinales bénéfiques qui la contiennent en tant qu'ingrédient actif. Selon la présente invention, les effets anti-obésité, antidiabétiques et d'activité œstrogénique et un effet de régulation du microbiote intestinal de la présente invention sont particulièrement excellents comparés à ceux d'un oligosaccharide d'acide mannuronique d'une extrémité non réductrice d'oligosaccharides d'acide mannuronique saturé. 본 발명은 폴리만뉴론산(poly-mannuronate) 기질로 하여 알긴산 라이아제(alginate lyase)에 의해 분해된 분자량 100-3000 Da 이하의 비환원성 말단의 불포화형 만뉴론산 올리고당에 관한 것으로, 상기 비환원성 말단의 불포화형 만뉴론산 올리고당 및 이를 유효성분으로 포함하는 비만, 당뇨 및 갱년기 증후군의 개선, 예방 또는 치료용 약제학적 조성물 및 장내 유익균 증진용 프로바이오틱스를 제공한다. 본 발명에 의하면, 본 발명의 항비만, 항당뇨, 에스트로겐 활성 및 장내 미생물 균총 조절 효과는 비환원성 말단의 포화형 만뉴론산 올리고당의 만뉴론산 올리고당과 비교하여 현저히 우수하다.